ethyl-biscoumacetate and Liver-Diseases

ethyl-biscoumacetate has been researched along with Liver-Diseases* in 6 studies

Trials

1 trial(s) available for ethyl-biscoumacetate and Liver-Diseases

Article	Year
[Use of hypoprothrombinemia provocation test for early diagnosis of liver disease caused by harmful environmental agents]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 1998, Volume: 4, Issue:21 The aim of this work has been to assess the feasibility of using Prothrombin Time (PT) Assay before and after administration of Pelentan (Hypoprothrombinemia Provocation (HPP) Test) for early detection of subclinical toxic hepatic injuries. The proposed modification of PT Assay is based on the observation that people with slight hepatic injury receiving small doses of Pelentan (diethylcoumarol) display remarkably longer PT than healthy people receiving similar doses of the chemical. The test group comprised 37 people occupationally exposed to hepatotoxic agents, 85 males permanently abusing alcohol, while 24 clinically healthy people, not exposed occupationally to the toxic agents served as the control. In addition, 26 hepatitis B and/or C virus carriers were also examined. The results show that: 1. HPP test enables assessment of hepatic function in patients with suspected hepatic injury and in people permanently abusing alcohol; 2. low value of serum prothrombin index 24 h and 48 h after the administration of Pelentan is indicative of the positive result of the test; 3. HPP test provides more information on the functional condition of liver than single PT determination by the Quick assay. Topics: Adult; Aged; Air Pollutants, Occupational; Alcoholism; Anticoagulants; Chemical and Drug Induced Liver Injury; Environmental Monitoring; Ethyl Biscoumacetate; Female; Humans; Hypoprothrombinemias; Liver Diseases; Liver Function Tests; Male; Middle Aged; Prothrombin Time	1998

Article

Year

[Use of hypoprothrombinemia provocation test for early diagnosis of liver disease caused by harmful environmental agents].

Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 1998, Volume: 4, Issue:21

The aim of this work has been to assess the feasibility of using Prothrombin Time (PT) Assay before and after administration of Pelentan (Hypoprothrombinemia Provocation (HPP) Test) for early detection of subclinical toxic hepatic injuries. The proposed modification of PT Assay is based on the observation that people with slight hepatic injury receiving small doses of Pelentan (diethylcoumarol) display remarkably longer PT than healthy people receiving similar doses of the chemical. The test group comprised 37 people occupationally exposed to hepatotoxic agents, 85 males permanently abusing alcohol, while 24 clinically healthy people, not exposed occupationally to the toxic agents served as the control. In addition, 26 hepatitis B and/or C virus carriers were also examined. The results show that: 1. HPP test enables assessment of hepatic function in patients with suspected hepatic injury and in people permanently abusing alcohol; 2. low value of serum prothrombin index 24 h and 48 h after the administration of Pelentan is indicative of the positive result of the test; 3. HPP test provides more information on the functional condition of liver than single PT determination by the Quick assay.

Topics: Adult; Aged; Air Pollutants, Occupational; Alcoholism; Anticoagulants; Chemical and Drug Induced Liver Injury; Environmental Monitoring; Ethyl Biscoumacetate; Female; Humans; Hypoprothrombinemias; Liver Diseases; Liver Function Tests; Male; Middle Aged; Prothrombin Time

1998

Other Studies

5 other study(ies) available for ethyl-biscoumacetate and Liver-Diseases

Article	Year
[Justification of anticoagulant prophylaxis of thromboembolisms in osteosynthesis of femoral fractures]. Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca, 1969, Volume: 36, Issue:3 Topics: Aged; Anticoagulants; Ethyl Biscoumacetate; Female; Femoral Fractures; Fracture Fixation; Humans; Liver Diseases; Male; Middle Aged; Prothrombin Time; Pulmonary Embolism; Thromboembolism	1969
CLINICAL ENZYMOLOGY. 2. Medical science, 1964, Volume: 15 Topics: Alanine Transaminase; Aspartate Aminotransferases; Brain Diseases; Clinical Enzyme Tests; Dicumarol; Ethyl Biscoumacetate; Heart Diseases; Humans; Infectious Mononucleosis; Liver Diseases; Muscular Diseases; Myocardial Infarction; Pancreatitis; Transaminases	1964
[Prevention with lipotropic factors of experimental liver damages and of severe hemorrhages caused by coumarin derivatives]. Wiener medizinische Wochenschrift (1946), 1957, Jul-06, Volume: 107, Issue:27 Topics: Coumarins; Ethyl Biscoumacetate; Hemorrhage; Lipotropic Agents; Liver Diseases	1957
[Polycythemia vera and the Budd-Chiari syndrome; clinical, biological & endoscopic study; traitement with P34 and tromexam; apparent recovery]. Revue medico-chirurgicale des maladies du foie, 1956, Volume: 31, Issue:2 Topics: Budd-Chiari Syndrome; Disease; Endoscopy; Ethyl Biscoumacetate; Hepatic Veins; Humans; Liver Diseases; Medical Records; Polycythemia Vera; Veins	1956
[Hypoprothrombinemia of ethyl ester of 4-4'-dioxydicumarinylacetic acid in hepatic diseases]. Rassegna giuliana di medicina, 1951, Volume: 7, Issue:1 Topics: Esters; Ethyl Biscoumacetate; Humans; Hypoprothrombinemias; Liver Diseases; Liver Function Tests	1951